Hypercortisolism and Epicardial Adipose Tissue

Assistance Publique Hopitaux De Marseille43 enrolled

Overview

Identifying hypercortisolism patients at risk for cardio-vascular events despite biological cure, and determine which patients should be particularly followed. Hypercortisolic patients represent an ideal in vivo model to determine the interactions between glucocorticoids and ectopic fat development.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Hypercortisolism

Interventions

Blood samples for measuring adiponectin, leptin and omentin plasmaBIOLOGICAL

MRI at 3 TeslaDEVICE

Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major, male or female * Introducing an active or healed hypercortisolism caused by Cushing's disease * signed informed consent. Exclusion Criteria: * Elderly patients under 18 years * Pregnant or lactating women * Previous history of myocardial infarction * Antecedent congenital cardiomyopathy * Adrenocorticotropic hormone-independent Hyperadrenocorticism * Hyperadrenocorticism by ectopic Adrenocorticotropic hormone secretion * Treatment with corticosteroids or insulin * Specific contraindication to the achievement of Nuclear Magnetic Resonance (metal heart valves, pacemakers, metallic foreign body, claustrophobia) * Persons deprived of liberty * Persons not affiliated to a social security scheme * People unable to give their consent in writing (in person or with the assistance of a third party).

Locations (1)

Assistance Publique Hôpitaux Marseille

Marseille, France

Outcomes

Primary Outcomes

measuring the volume of epicardial adipose tissue, as measured by MRI to 3 Tesla.

Time frame: 36 months

Assess insulin resistance by the blood sugar and insulin levels

Time frame: 36 months

Assess cardiovascular risk by a blood complete lipid profile

Time frame: 36 months

Secondary Outcomes

Assess insulin resistance by the blood leptin, adiponectin and omentin plasma level

Time frame: 36 months

Assess cardiovascular risk by the blood leptin, adiponectin and omentin plasma level

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.